Cardioprotective effect of ranolazine in nondiabetic and diabetic male rats subjected to isoprenaline-induced acute myocardial infarction involves modulation of AMPK and inhibition of apoptosis
Authors:
- 1 July 2019
- journal article
- research article
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 97 (7) , 661-674
Abstract
Diabetes increases the sensitivity of myocardium to ischemic damage and impairs response of the myocardium to cardioprotective interventions. The present study aimed to elucidate the potential cardioprotective effect provided by ranolazine during myocardial infarction in nondiabetic and diabetic male rats. As AMP-activated protein kinase (AMPK) has been shown to be involved in the cellular response to ischemic injury, in this context, the present animal study evaluated the modulating role of ranolazine in the AMPK expression in isoprenaline-induced myocardial ischemic rat model. Male rats were divided into 2 experiments: experiment I and II (nondiabetic and diabetic rats) and assigned to normal control, saline control for isoprenaline, isoprenaline control, and ranolazine-treated groups. Ranolazine administration revealed effectiveness in attenuating the severity of isoprenaline-induced myocardial injury in both nondiabetic and diabetic rats as revealed by ECG signs, histopathological score, and apoptotic markers via abrogating the increments in the inflammatory and oxidative stress markers and modulating AMPK expression. Therefore, the current cardioprotective effect of ranolazine was, at least in part, mediated through inhibition of apoptosis and modulation of AMPK expression, encouraging considering the utility of ranolazine in protection from acute myocardial infarction.Keywords
This publication has 60 references indexed in Scilit:
- Intermedin protects against myocardial ischemia-reperfusion injury in diabetic ratsCardiovascular Diabetology, 2013
- Type 2 diabetic obese db/db mice are refractory to myocardial ischaemic post‐conditioning in vivo: potential role for Hsp20, F1‐ATPase δ and Echs1Journal of Cellular and Molecular Medicine, 2012
- Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioningCardiovascular Diabetology, 2012
- Hematopoietic AMPK β1 reduces mouse adipose tissue macrophage inflammation and insulin resistance in obesityJournal of Clinical Investigation, 2011
- Effect of Ranolazine on A1C and Glucose Levels in Hyperglycemic Patients With Non-ST Elevation Acute Coronary SyndromeDiabetes Care, 2010
- Diabetes prevalence and diagnosis in US states: analysis of health surveysPopulation Health Metrics, 2009
- Changes in Diastolic Dysfunction in Diabetes Mellitus Over TimeThe American Journal of Cardiology, 2009
- Mortality after myocardial infarction in patients with diabetes mellitusHeart, 2007
- Role of AMP-activated protein kinase in healthy and diseased heartsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- LIPID PEROXIDATION AND ANTIOXIDANT ENZYMES IN ISOPROTERENOL INDUCED OXIDATIVE STRESS IN RAT TISSUESPharmacological Research, 1998